Literature DB >> 22089350

Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults.

Prerana Jha1, Vaishali Suri, Geetika Singh, Pankaj Jha, Suvendu Purkait, Pankaj Pathak, Vikas Sharma, Mehar Chand Sharma, Ashish Suri, Deepak Gupta, Ashok Kumar Mahapatra, Chitra Sarkar.   

Abstract

To evaluate age-related differences in histopathologic and molecular profile of glioblastomas (GBMs) at various age groups, with special reference to TP53 mutation, epidermal growth factor receptor (EGFR) amplification, EGFR vIII mutant, PTEN deletion, and IDH1 mutation. Agewise GBM incidence was calculated over a period of 5 years (2005 to 2009). Seventy-five GBMs were selected for molecular analysis. Majority of cases were in the age group of 41 to 60 years, and mean age was 43.6 years. Histology of all 75 cases selected for molecular profiling was identical. Primary adult GBMs showed EGFR amplification and PTEN deletion in majority (37.3% and 54.9%, respectively). TP53 and IDH1 mutations were rare (11.8% cases each). In secondary GBMs, TP53 (66.7%) and IDH1 mutations (44.4%) were most frequent. PTEN deletion was seen in 33.3% and none had EGFR amplification. Pediatric GBMs (<18 y) harbored frequent TP53 mutations (46.7%) and PTEN deletion in 40%. IDH1 mutations and EGFR amplification were absent. The molecular profile of primary GBMs in young adults (19 to 40 y) was distinctly different from that of adults older than 40 years. TP53 mutation was present in 20% cases. The frequency of EGFR amplification (13.3%) and PTEN deletion (33.3%) was significantly low (P=0.028 and 0.046, respectively). IDH1 mutation, which is rare in primary adult GBMs, was present in 40% of cases. Molecular heterogeneity exists within GBMs of different age cohorts. The molecular profile of GBMs in young adults is distinctly different. Thus, there is a strong need for further studies in various age groups to provide guidelines for therapeutic targeting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22089350     DOI: 10.1097/PDM.0b013e31821c30bc

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  20 in total

1.  Molecular profile of oligodendrogliomas in young patients.

Authors:  Vaishali Suri; Prerana Jha; Shipra Agarwal; Pankaj Pathak; Mehar Chand Sharma; Vikas Sharma; Sudhanshu Shukla; Kumaravel Somasundaram; Ashok Kumar Mahapatra; Shashank Sharad Kale; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2011-10       Impact factor: 12.300

2.  Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.

Authors:  Prit Benny Malgulwar; Aruna Nambirajan; Pankaj Pathak; Mohammed Faruq; Vaishali Suri; Chitra Sarkar; Amandeep Jagdevan; Bhawani Shankar Sharma; Mehar Chand Sharma
Journal:  J Neurooncol       Date:  2017-05-12       Impact factor: 4.130

Review 3.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

4.  Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database.

Authors:  Lyubov E Salnikova
Journal:  Neuromolecular Med       Date:  2014-01-31       Impact factor: 3.843

Review 5.  Treatment of Glioblastoma in the Elderly.

Authors:  Rebecca A Harrison; John F de Groot
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

6.  Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).

Authors:  Annette Leibetseder; Michael Ackerl; Birgit Flechl; Adelheid Wöhrer; Georg Widhalm; Karin Dieckmann; Sabine-Spiegl Kreinecker; Josef Pichler; Johannes Hainfellner; Matthias Preusser; Christine Marosi
Journal:  Neuro Oncol       Date:  2012-12-07       Impact factor: 12.300

7.  Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.

Authors:  Daniel I Hoffman; Kalil G Abdullah; Makayla McCoskey; Zev A Binder; Donald M O'Rourke; Arati S Desai; MacLean P Nasrallah; Ashkan Bigdeli; Jennifer J D Morrissette; Steven Brem; Stephen J Bagley
Journal:  J Neurooncol       Date:  2019-09-21       Impact factor: 4.130

8.  Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.

Authors:  Prerana Jha; Irene Rosita Pia Patric; Sudhanshu Shukla; Pankaj Pathak; Jagriti Pal; Vikas Sharma; Sivaarumugam Thinagararanjan; Vani Santosh; Vaishali Suri; Mehar Chand Sharma; Arimappamagan Arivazhagan; Ashish Suri; Deepak Gupta; Kumaravel Somasundaram; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2014-07-04       Impact factor: 12.300

9.  Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.

Authors:  Benedikt Wiestler; Rainer Claus; Sabine A Hartlieb; Maximilian G Schliesser; Elisa K Weiss; Thomas Hielscher; Michael Platten; Laura M Dittmann; Christoph Meisner; Jörg Felsberg; Caroline Happold; Matthias Simon; Guido Nikkhah; Kirsten Papsdorf; Joachim P Steinbach; Michael Sabel; Christiane Grimm; Dieter Weichenhan; Björn Tews; Guido Reifenberger; David Capper; Wolf Müller; Christoph Plass; Michael Weller; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2013-04-17       Impact factor: 12.300

10.  Pediatric glioblastoma: a single institution experience.

Authors:  Marina Nikitović; Dragana Stanić; Tatjana Pekmezović; Milica Skender Gazibara; Jelena Bokun; Lejla Paripović; Danica Grujičić; Milan Sarić; Ivana Mišković
Journal:  Childs Nerv Syst       Date:  2015-11-04       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.